<p>Praxis Investment Management Inc. 在最近向證券交易委員會的披露中表示，在第二季度將其在因塞特醫療（Incyte Corporation，NASDAQ:INCY - 免費報告）的股份增加了 82.2%。這家機構投資者在此期間購買了 3,150 股後，持有該生物製藥公司 6,980 股股票。根據其最近的 SEC 文件，Praxis Investment Management Inc.在因塞特醫療的持股價值為 475,000 美元。</p>
<ul>
<li>因塞特醫療能否實現 447% 的每股收益預測和管道熱度？</li>
</ul>
<p>其他對沖基金和機構投資者最近也買賣了該公司的股票。Banque Transatlantique SA 在第一季度以 26,000 美元的估值購買了因塞特醫療的新股份。Hilltop National Bank 在第二季度購買了約 37,000 美元的因塞特醫療股份。SVB Wealth LLC 在第一季度以約 39,000 美元的估值購買了因塞特醫療的新股份。Geneos Wealth Management Inc.在第一季度將其在因塞特醫療的持股增加了 350.0%。Geneos Wealth Management Inc.現在擁有 756 股該生物製藥公司的股票，價值 46,000 美元，此前在上個季度又購買了 588 股。最後，WPG Advisers LLC 在第一季度以約 47,000 美元的估值購買了因塞特醫療的新股份。96.97% 的股票由機構投資者持有。</p>
<h2>因塞特醫療的內部交易</h2>
<p>在因塞特醫療的其他消息中，執行副總裁 Steven H. Stein 於 7 月 21 日星期一出售了 3,706 股公司的股票。股票以平均價格 67.94 美元出售，總價值為 251,785.64 美元。出售完成後，該執行副總裁直接持有 102,886 股公司的股票，價值約為 6,990,074.84 美元。這代表其持股減少了 3.48%。該出售在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。在過去的九十天裏，內部人士已出售 4,261 股公司股票，價值 298,482 美元。公司內部人士持有 17.80% 的公司股票。</p>
<h2>華爾街分析師的看法</h2>
<ul>
<li>2024 年盈利增長的五大醫療股</li>
</ul>
<p>幾位股票研究分析師最近對 INCY 股票發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對因塞特醫療股票的 “持有（c+）” 評級。美國銀行在 9 月 4 日的研究報告中將因塞特醫療股票的目標價格從 90.00 美元提高到 104.00 美元，並給予該股票 “買入” 評級。巴克萊在 8 月 1 日的研究報告中開始覆蓋因塞特醫療股票。他們為該公司設定了 “增持” 評級和 90.00 美元的目標價格。富國銀行在 8 月 6 日的研究報告中將因塞特醫療股票的評級從 “持平” 提升至 “增持”，並將該股票的目標價格從 67.00 美元提高到 89.00 美元。最後，Truist Financial 在 7 月 30 日的研究報告中將因塞特醫療股票的目標價格從 73.00 美元提高到 79.00 美元，並給予該股票 “持有” 評級。一位股票研究分析師對該股票給予了強烈買入評級，五位分析師給予了買入評級，十二位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，因塞特醫療目前的平均評級為 “持有”，平均目標價格為 84.79 美元。</p>
<p><strong>查看我們最新的因塞特醫療股票報告</strong></p>
<h2>因塞特醫療股票上漲 0.3%</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的產品提升了投資者信心</li>
</ul>
<p>因塞特醫療的 INCY 股票在週五開盤價為 87.57 美元。因塞特醫療的 52 周低點為 53.56 美元，52 周高點為 92.86 美元。該公司的債務與股本比率為 0.01，速動比率為 2.78，流動比率為 2.85。該公司的 50 日簡單移動平均為 85.20 美元，200 日簡單移動平均為 72.54 美元。該公司的市值為 171 億美元，市盈率為 19.90，PEG 比率為 0.68，貝塔值為 0.73。</p>
<h2>因塞特醫療簡介</h2>
<p>（免費報告）</p>
<p>因塞特醫療公司是一家生物製藥公司，專注於血液學/腫瘤學、炎症和自身免疫領域的治療藥物的發現、開發和商業化。該公司提供 JAKAFI（ruxolitinib）用於治療中度或高風險的骨髓纖維化、真性紅細胞增多症和類固醇耐藥性急性移植物抗宿主病；MONJUVI（tafasitamab-cxix）/MINJUVI（tafasitamab）用於復發或難治性瀰漫性大 B 細胞淋巴瘤；PEMAZYRE（pemigatinib），一種成纖維細胞生長因子受體激酶抑制劑，作為液體和實體腫瘤類型的致癌驅動因子；ICLUSIG（ponatinib）用於治療慢性髓性白血病和費城染色體陽性急性淋巴細胞白血病；以及 OPZELURA 乳膏用於治療特應性皮炎。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過因塞特醫療</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>強生的併購策略是投資者真正關注的故事</li>
<li>電話會議和個人投資者</li>
<li>特斯拉：一些分析師預測將下跌 30%——是時候恐慌了嗎？</li>
<li>低市盈率增長股票：解鎖投資機會</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 INCY 股票嗎？</strong> 訪問 HoldingsChannel.com 獲取因塞特醫療公司（NASDAQ:INCY - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ"/></p>
<p><em>此即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在因塞特醫療嗎？</h2>
<p>在考慮因塞特醫療之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而因塞特醫療並不在名單上。</p>
<p>雖然因塞特醫療目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

因塞特醫療

<p>Praxis Investment Management Inc. 在第二季度將其在因塞特醫療的股份增加了 82.2%，額外購買了 3,150 股，使其總持股達到 6,980 股，價值 475,000 美元。其他機構投資者最近也購買了該公司的股票。因塞特醫療的股票在過去 52 周的價格範圍為 53.56 美元至 92.86 美元，目前價格為 87.57 美元。分析師對該股票的評級不一，平均目標價為 84.79 美元。因塞特醫療專注於血液學/腫瘤學和炎症治療</p>

<p>Praxis Investment Management Inc. raised its stake in Incyte Corporation (NASDAQ:INCY - Free Report) by 82.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,980 shares of the biopharmaceutical company's stock after purchasing an additional 3,150 shares during the period. Praxis Investment Management Inc.'s holdings in Incyte were worth $475,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Praxis Investment Management Inc. 在最近向證券交易委員會的披露中表示，在第二季度將其在因塞特醫療（Incyte Corporation，NASDAQ:INCY - 免費報告）的股份增加了 82.2%。這家機構投資者在此期間購買了 3,150 股後，持有該生物製藥公司 6,980 股股票。根據其最近的 SEC 文件，Praxis Investment Management Inc.在因塞特醫療的持股價值為 475,000 美元。</p>
</div><ul>
<li>Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>因塞特醫療能否實現 447% 的每股收益預測和管道熱度？</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Transatlantique SA bought a new stake in Incyte in the first quarter valued at $26,000. Hilltop National Bank bought a new stake in shares of Incyte during the second quarter worth about $37,000. SVB Wealth LLC bought a new stake in shares of Incyte during the first quarter worth about $39,000. Geneos Wealth Management Inc. increased its position in shares of Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company's stock worth $46,000 after acquiring an additional 588 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of Incyte during the first quarter worth about $47,000. 96.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者最近也買賣了該公司的股票。Banque Transatlantique SA 在第一季度以 26,000 美元的估值購買了因塞特醫療的新股份。Hilltop National Bank 在第二季度購買了約 37,000 美元的因塞特醫療股份。SVB Wealth LLC 在第一季度以約 39,000 美元的估值購買了因塞特醫療的新股份。Geneos Wealth Management Inc.在第一季度將其在因塞特醫療的持股增加了 350.0%。Geneos Wealth Management Inc.現在擁有 756 股該生物製藥公司的股票，價值 46,000 美元，此前在上個季度又購買了 588 股。最後，WPG Advisers LLC 在第一季度以約 47,000 美元的估值購買了因塞特醫療的新股份。96.97% 的股票由機構投資者持有。</p>
</div><h2>Insider Transactions at Incyte</h2>
<div class="lb-trans"><h2>因塞特醫療的內部交易</h2>
</div><p>In other Incyte news, EVP Steven H. Stein sold 3,706 shares of the company's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $67.94, for a total value of $251,785.64. Following the completion of the sale, the executive vice president directly owned 102,886 shares of the company's stock, valued at approximately $6,990,074.84. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 4,261 shares of company stock valued at $298,482. Corporate insiders own 17.80% of the company's stock.</p>
<div class="lb-trans"><p>在因塞特醫療的其他消息中，執行副總裁 Steven H. Stein 於 7 月 21 日星期一出售了 3,706 股公司的股票。股票以平均價格 67.94 美元出售，總價值為 251,785.64 美元。出售完成後，該執行副總裁直接持有 102,886 股公司的股票，價值約為 6,990,074.84 美元。這代表其持股減少了 3.48%。該出售在向 SEC 提交的文件中披露，文件可通過 SEC 網站訪問。在過去的九十天裏，內部人士已出售 4,261 股公司股票，價值 298,482 美元。公司內部人士持有 17.80% 的公司股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年盈利增長的五大醫療股</li>
</ul>
</div><p>Several equities research analysts have recently commented on INCY shares. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Incyte in a research report on Wednesday, October 8th. Bank of America boosted their target price on shares of Incyte from $90.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, September 4th. Barclays started coverage on shares of Incyte in a research report on Friday, August 1st. They set an &#34;overweight&#34; rating and a $90.00 target price for the company. Wells Fargo &amp; Company raised shares of Incyte from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their target price for the stock from $67.00 to $89.00 in a research report on Wednesday, August 6th. Finally, Truist Financial boosted their target price on shares of Incyte from $73.00 to $79.00 and gave the stock a &#34;hold&#34; rating in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Incyte currently has an average rating of &#34;Hold&#34; and an average price target of $84.79.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 INCY 股票發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對因塞特醫療股票的 “持有（c+）” 評級。美國銀行在 9 月 4 日的研究報告中將因塞特醫療股票的目標價格從 90.00 美元提高到 104.00 美元，並給予該股票 “買入” 評級。巴克萊在 8 月 1 日的研究報告中開始覆蓋因塞特醫療股票。他們為該公司設定了 “增持” 評級和 90.00 美元的目標價格。富國銀行在 8 月 6 日的研究報告中將因塞特醫療股票的評級從 “持平” 提升至 “增持”，並將該股票的目標價格從 67.00 美元提高到 89.00 美元。最後，Truist Financial 在 7 月 30 日的研究報告中將因塞特醫療股票的目標價格從 73.00 美元提高到 79.00 美元，並給予該股票 “持有” 評級。一位股票研究分析師對該股票給予了強烈買入評級，五位分析師給予了買入評級，十二位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，因塞特醫療目前的平均評級為 “持有”，平均目標價格為 84.79 美元。</p>
</div><p><strong>View Our Latest Stock Report on Incyte</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的因塞特醫療股票報告</strong></p>
</div><h2>Incyte Trading Up 0.3%</h2>
<div class="lb-trans"><h2>因塞特醫療股票上漲 0.3%</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的產品提升了投資者信心</li>
</ul>
</div><p>Shares of INCY stock opened at $87.57 on Friday. Incyte Corporation has a 52-week low of $53.56 and a 52-week high of $92.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.78 and a current ratio of 2.85. The company has a 50-day simple moving average of $85.20 and a two-hundred day simple moving average of $72.54. The company has a market capitalization of $17.10 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 0.68 and a beta of 0.73.</p>
<div class="lb-trans"><p>因塞特醫療的 INCY 股票在週五開盤價為 87.57 美元。因塞特醫療的 52 周低點為 53.56 美元，52 周高點為 92.86 美元。該公司的債務與股本比率為 0.01，速動比率為 2.78，流動比率為 2.85。該公司的 50 日簡單移動平均為 85.20 美元，200 日簡單移動平均為 72.54 美元。該公司的市值為 171 億美元，市盈率為 19.90，PEG 比率為 0.68，貝塔值為 0.73。</p>
</div><h2>Incyte Profile</h2>
<div class="lb-trans"><h2>因塞特醫療簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.</p>
<div class="lb-trans"><p>因塞特醫療公司是一家生物製藥公司，專注於血液學/腫瘤學、炎症和自身免疫領域的治療藥物的發現、開發和商業化。該公司提供 JAKAFI（ruxolitinib）用於治療中度或高風險的骨髓纖維化、真性紅細胞增多症和類固醇耐藥性急性移植物抗宿主病；MONJUVI（tafasitamab-cxix）/MINJUVI（tafasitamab）用於復發或難治性瀰漫性大 B 細胞淋巴瘤；PEMAZYRE（pemigatinib），一種成纖維細胞生長因子受體激酶抑制劑，作為液體和實體腫瘤類型的致癌驅動因子；ICLUSIG（ponatinib）用於治療慢性髓性白血病和費城染色體陽性急性淋巴細胞白血病；以及 OPZELURA 乳膏用於治療特應性皮炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Incyte</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>Conference Calls and Individual Investors</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過因塞特醫療</li>
<li>頂級生物技術股票：探索創新機會</li>
<li>強生的併購策略是投資者真正關注的故事</li>
<li>電話會議和個人投資者</li>
<li>特斯拉：一些分析師預測將下跌 30%——是時候恐慌了嗎？</li>
<li>低市盈率增長股票：解鎖投資機會</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding INCY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 INCY 股票嗎？</strong> 訪問 HoldingsChannel.com 獲取因塞特醫療公司（NASDAQ:INCY - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5DWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=INCY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍事科學技術和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Incyte Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在因塞特醫療嗎？</h2>
</div><p>Before you consider Incyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮因塞特醫療之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而因塞特醫療並不在名單上。</p>
</div><p>While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然因塞特醫療目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Praxis Investment Management Inc. 購入了 3,150 股因塞特醫療公司（Incyte Corporation）的股票 $INCY